US Bancorp DE Sells 4,587 Shares of Certara, Inc. (NASDAQ:CERT)

US Bancorp DE reduced its position in Certara, Inc. (NASDAQ:CERT) by 28.4% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 11,575 shares of the company’s stock after selling 4,587 shares during the period. US Bancorp DE’s holdings in Certara were worth $136,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Blue Trust Inc. purchased a new stake in shares of Certara during the 2nd quarter valued at approximately $26,000. Innealta Capital LLC bought a new stake in Certara during the 2nd quarter valued at $36,000. Intech Investment Management LLC bought a new stake in Certara during the 2nd quarter valued at $152,000. Algert Global LLC purchased a new stake in shares of Certara during the second quarter worth $156,000. Finally, MQS Management LLC bought a new position in shares of Certara in the second quarter worth $162,000. 73.96% of the stock is owned by hedge funds and other institutional investors.

Certara Price Performance

Shares of NASDAQ CERT opened at $9.96 on Friday. The stock’s 50-day simple moving average is $10.90 and its two-hundred day simple moving average is $13.49. Certara, Inc. has a twelve month low of $9.88 and a twelve month high of $19.87. The firm has a market capitalization of $1.60 billion, a P/E ratio of -49.80, a P/E/G ratio of 5.46 and a beta of 1.51. The company has a quick ratio of 2.86, a current ratio of 2.86 and a debt-to-equity ratio of 0.28.

Certara (NASDAQ:CERT) last posted its quarterly earnings data on Wednesday, November 6th. The company reported $0.13 earnings per share for the quarter, topping the consensus estimate of $0.11 by $0.02. Certara had a negative net margin of 8.34% and a positive return on equity of 3.43%. The company had revenue of $94.80 million for the quarter, compared to analysts’ expectations of $95.51 million. During the same period in the prior year, the business earned $0.06 earnings per share. Certara’s revenue for the quarter was up 10.7% compared to the same quarter last year. As a group, equities analysts anticipate that Certara, Inc. will post 0.28 EPS for the current fiscal year.

Insider Transactions at Certara

In other Certara news, insider Patrick F. Smith sold 5,409 shares of the company’s stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $11.03, for a total value of $59,661.27. Following the completion of the sale, the insider now owns 50,091 shares of the company’s stock, valued at $552,503.73. This represents a 9.75 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Leif E. Pedersen sold 51,224 shares of Certara stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $11.29, for a total transaction of $578,318.96. Following the transaction, the insider now directly owns 99,704 shares in the company, valued at $1,125,658.16. This trade represents a 33.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 2.39% of the company’s stock.

Analyst Upgrades and Downgrades

CERT has been the topic of a number of analyst reports. Barclays decreased their price objective on Certara from $14.00 to $12.00 and set an “equal weight” rating on the stock in a research note on Thursday, November 7th. UBS Group raised Certara from a “neutral” rating to a “buy” rating and set a $16.00 target price for the company in a report on Friday, September 27th. Finally, Robert W. Baird lowered their price target on shares of Certara from $18.00 to $13.00 and set a “neutral” rating on the stock in a report on Tuesday, November 5th. Six investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat, Certara presently has an average rating of “Hold” and an average price target of $15.92.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.